Some of the latest scientific studies reviewed
sound provided by mansardian and tyops @freesound.org
Antibody testing
Wu, Jun, et al. “SARS-CoV-2 Infection Induces Sustained Humoral Immune Responses in
Convalescent Patients Following Symptomatic COVID-19.” MedRxiv, 2020,
doi:10.1101/2020.07.21.20159178.
Iyer, Jones, et al. “Dynamics and significance of the antibody response to SARS-CoV-2
infection.” MedRxiv, 2020, doi:10.1101/2020.07.18.20155374.
Pepper, Rodda, et al. “Functional SARS-CoV-2-specific immune memory persists after mild
COVID-19.” MedRxiv, 2020, doi: .
Bhattacharya, Ripperger, et al. “Detection, prevalence, and duration of humoral responses to
SARS-CoV-2 under conditions of limited population exposure.” MedRxiv, 2020, doi:
Buggert, Sekine, et al. “Robust T cell immunity in convalescent individuals with asymptomatic
or mild COVID-19.” Cell, 2020, doi:
Gringas, Isho, et al. “Evidence for sustained mucosal and systemic antibody responses to SARS-
CoV-2 antigens in COVID-19 patients.” MedRxiv, 2020, doi:
Heard Immunity
Britton, Ball, & Trapman. “A mathematical model reveals the influence of population
heterogeneity on herd immunity to SARS-CoV-2.” Science, 2020, doi:
10.1126/science.abc6810.
Gomes, et al. “Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd
immunity threshold.” MedRxiv, 2020, doi: .
Glycyrrhizin
Cinatl, Morgenstern, Bauer, Chandra, Rabenau, & Doerr. “Glycyrrhizin,
an active component of liquorice roots, and replication of SARS-associated
coronavirus.” Lancet, 2003, doi:
Hoever, Baltina, Michaelis, Kondratenko, Tolstikov, & Doerr et al. “Antiviral activity of
glycyrrhizic acid derivatives against SARS-coronavirus.” J Med Chem, 2005, doi:
Fujii, Nakamura, & Iwamoto . “Current concepts in SARS treatment.” J Infect
Chemother, 2004, doi: 10.1007/s10156-003-0296-9.
Two open label clinical trials for Glycrrhizin are registered on the WHO clinical trial registration
website, a randomized open label trial (ChiCTR2000029768) and a case series
(ChiCTR2000030490).
Vaccine Trial Numbers:
NCT04348370 – BCG vaccine
NCT04470427 – mRNA 1273 vaccine
NCT04516746 – AZD1222 vaccine
